The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL)

被引：0

作者：

Kuruvilla, John ^{[1
]}

Byrd, John C. ^{[2
]}

Flynn, Joseph M. ^{[3
]}

Garzon, Ramiro ^{[3
]}

Porcu, Pierluigi ^{[2
]}

Wagner-Johnston, Nina ^{[4
]}

Savoie, Mary Lynn ^{[5
]}

Stone, Richard M. ^{[6
]}

Jacobsen, Eric D. ^{[6
]}

Mau-Sorensen, Morten ^{[7
]}

Brown, Peter de Nully ^{[8
]}

Baz, Rachid ^{[9
]}

Shal, Bijal ^{[9
]}

Flinn, Ian ^{[10
]}

Gabrail, Nashat ^{[11
]}

Kukreti, Vishal ^{[12
]}

Tiedemann, Rodger E. ^{[12
]}

Landesman, Yosef ^{[13
]}

Klebanov, Boris ^{[13
]}

Shacham, Eran ^{[13
]}

Saint-Martin, Jean-Richard ^{[13
]}

Marshall, Tracey ^{[13
]}

McCartney, John ^{[13
]}

McCauley, Dilara ^{[13
]}

Carlson, Robert ^{[13
]}

Norori, Sasha ^{[14
]}

Savona, Michael R. ^{[13
]}

Rashal, Tami ^{[13
]}

Mirza, Mansoor R. ^{[13
]}

Kauffman, Michael ^{[13
]}

Shacham, Sharon ^{[13
]}

机构：

[1] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[5] Alberta Hlth Serv, Calgary, AB, Canada

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark

[8] Rigshosp, DK-2100 Copenhagen, Denmark

[9] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Gabrail Canc Ctr, Canton, OH USA

[12] Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Karyopharm Therapeut Inc, Newton, MA USA

[14] Ozmosis Res Inc, Toronto, ON, Canada

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACI), demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL)
Spencer, A.
DeAngelo, D. J.
Prince, H. M.
Bhalla, K. N.
Fischer, T.
Liu, A.
Parker, K.
Jalaluddin, M.
Scott, J. W.
Ottmann, O. G.
ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
[42] Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Witzig, Thomas E.
Wiernik, Peter H.
Moore, Timothy
Reeder, Craig
Cole, Craig
Justice, Glen
Kaplan, Henry
Voralia, Michael
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Vose, Julie M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5404 - 5409
[43] A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma
Cornell, R. Frank
Rossi, Adriana C.
Baz, Rachid
Hofmeister, Craig C.
Shustik, Chaim
Richter, Joshua R.
Chen, Christine
Vogl, Dan T.
Shacham, Sharon
Baloglu, Erkan
Senapedis, William
Ellis, Joel
Friedlander, Sharon
Choe-Juliak, Cassandra
Cubitt, Christopher L.
Turner, Joel G.
Sullivan, Daniel
Kauffman, Michael
BLOOD, 2016, 128 (22)
[44] Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
Muqbil, Irfana
Aboukameel, Amro
Elloul, Sivan
Carlson, Robert
Senapedis, William
Baloglu, Erkan
Kauffman, Michael
Shacham, Sharon
Bhutani, Divaya
Zonder, Jeffrey
Azmi, Asfar S.
Mohammad, Ramzi M.
CANCER LETTERS, 2016, 383 (02) : 309 - 317
[45] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
Witzig, T. E.
Wiernik, P. H.
Moore, T.
Reeder, C.
Cole, C.
Justice, G.
Kaplan, H.
Voralia, M.
Pietronigro, D.
Vose, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[46] Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
Strauss, SJ
Maharaj, L
Stec, J
Boral, A
Trehu, E
Schenkein, D
Joel, SP
Lister, TA
BLOOD, 2004, 104 (11) : 389A - 389A
[47] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
Younes, A.
Kuruvilla, J.
Pro, B.
Wedgwood, A.
Li, Z.
Drouin, M.
Patterson, T.
Ward, R.
Martell, R. E.
Bociek, R. G.
ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
[48] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
Bociek, R. G.
Kuruvilla, J.
Pro, B.
Wedgwood, A.
Li, Z.
Drouin, M.
Patterson, T.
Ward, R.
Martell, R. E.
Younes, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[49] Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells
Etchin, Julia
Le, Bonnie Thi
Berezovskaya, Alla
Conway, Amy S.
Chen, Weihsu C.
Kentsis, Alex
Mansour, Marc R.
Stone, Richard M.
Galinsky, Ilene A.
DeAngelo, Daniel J.
McCauley, Dilara
Kauffman, Michael
Shacham, Sharon
Wang, Jean C. Y.
Kung, Andrew L.
Look, Thomas
CANCER RESEARCH, 2015, 75
[50] Results of a phase II trial of selinexor, an oral selective inhibitor of nuclear export (SINE), in patients with metastatic castration resistant prostate cancer (mCRPC) refractory to abiraterone or enzalutamide.
Wei, Xiao
Siegel, Adam Phillip
Aggarwal, Rahul Raj
Lin, Amy M.
Friedlander, Terence W.
Fong, Lawrence
Paraganlija, Mirela
Chang, Emily
Zhang, Li
Ryan, CharlesJ.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →